

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

Case No. 4574

**THE MEDICINE SHOPPE
3024 Pacific Avenue
Livermore, CA 94550**

Pharmacy License No. PHY 48618

Respondent.

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This decision shall become effective on July 22, 2015.

It is so ORDERED on July 15, 2015.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA



By

AMARYLIS GUTIERREZ
Board President

1 KAMALA D. HARRIS
Attorney General of California
2 JOSHUA A. ROOM
Supervising Deputy Attorney General
3 MARETTA WARD
Deputy Attorney General
4 State Bar No. 176470
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 703-1384
6 Facsimile: (415) 703-5480
Attorneys for Complainant

7
8 **BEFORE THE**
BOARD OF PHARMACY
9 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

10 In the Matter of the Accusation Against:

Case No. 4574

11 **THE MEDICINE SHOPPE**
12 **3024 Pacific Avenue**
13 **Livermore, CA 94550**

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER

14 **Pharmacy License No. PHY 48618**

15
16 Respondent.

17
18 **IT IS HEREBY STIPULATED AND AGREED** by and between the parties to the above-
19 entitled proceedings that the following matters are true:

20 **PARTIES**

21 1. Virginia Herold ("Complainant") is the Executive Officer of the Board of Pharmacy.
22 She brought this action solely in her official capacity and is represented in this matter by Kamala
23 D. Harris, Attorney General of the State of California, by Maretta Ward, Deputy Attorney
24 General.

25 2. Respondent The Medicine Shoppe ("Respondent") is represented in this proceeding
26 by attorney Tony Park, whose address is: 2855 Michelle Drive, Suite 180
27 Irvine, CA 92606-1027.

28 //

JURISDICTION

5. A copy of Accusation No. 4574 is attached as exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.



9. Respondent admits the truth of each and every charge and allegation in Accusation No. 4574.

10. Respondent agrees that its Pharmacy License is subject to discipline and they agree to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

11. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent or its counsel. By signing the stipulation, Respondent understands and agrees that it may not withdraw its agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.

12. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including Portable Document Format (PDF) and facsimile signatures thereto, shall have the same force and effect as the originals.

13: This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

14. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

11

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Pharmacy License No. PHY 48618 issued to Puchkar International LLC; Pushkar International Inc., to do business as "The Medicine Shoppe" (Respondent Medicine Shoppe) is revoked. However, the revocation is stayed and Respondent is placed on probation for four (4) years on the following terms and conditions.

1. Obey All Laws

Respondent owner shall obey all state and federal laws and regulations.

Respondent owner shall report any of the following occurrences to the Board, in writing, within seventy-two (72) hours of such occurrence:

- ☐ an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- ☐ a plea of guilty or nolo contendere in any state or federal criminal proceeding to any criminal complaint, information or indictment
- ☐ a conviction of any crime
- ☐ discipline, citation, or other administrative action filed by any state or federal agency which involves Respondent's Pharmacy License or which is related to the practice of pharmacy or the manufacturing, obtaining, handling or distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

2. Report to the Board

Respondent owner shall report to the Board quarterly, on a schedule as directed by the Board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, Respondent owner shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be

1 automatically extended until such time as the final report is made and accepted by the Board.

2 **3. Interview with the Board**

3 Upon receipt of reasonable prior notice, Respondent owner shall appear in person for
4 interviews with the Board or its designee, at such intervals and locations as are determined by the
5 Board or its designee. Failure to appear for any scheduled interview without prior notification to
6 Board staff, or failure to appear for two (2) or more scheduled interviews with the Board or its
7 designee during the period of probation, shall be considered a violation of probation.

8 **4. Cooperate with Board Staff**

9 Respondent owner shall cooperate with the Board's inspection program and with the
10 Board's monitoring and investigation of Respondent's compliance with the terms and conditions
11 of their probation. Failure to cooperate shall be considered a violation of probation.

12 **5. Reimbursement of Board Costs**

13 As a condition precedent to successful completion of probation, Respondent owner shall
14 pay to the Board its costs of investigation and prosecution in the amount of \$17,267.00.
15 Respondent owner shall make said payments as follows: Payments can be made on a payment
16 plan approved by the Board or its designee. There shall be no deviation from this schedule absent
17 prior written approval by the Board or its designee. Failure to pay costs by the deadline(s) as
18 directed shall be considered a violation of probation.

19 The filing of bankruptcy by Respondent owner shall not relieve Respondent of their
20 responsibility to reimburse the Board its costs of investigation and prosecution.

21 Respondent shall be jointly and severally liable for payment of costs of investigation and
22 prosecution with Respondent Priti Chatwani.

23 **6. Probation Monitoring Costs**

24 Respondent owner shall pay any costs associated with probation monitoring as determined
25 by the Board each and every year of probation. Such costs shall be payable to the Board on a
26 schedule as directed by the Board or its designee. Failure to pay such costs by the deadline(s) as
27 directed shall be considered a violation of probation.

28 / /

1 **7. Status of License**

2 Respondent owner shall, at all times while on probation, maintain current licensure with the
3 Board. If Respondent owner submits an application to the Board, and the application is approved,
4 for a change of location, change of permit or change of ownership, the Board shall retain
5 continuing jurisdiction over the license, and the Respondent shall remain on probation as
6 determined by the Board. Failure to maintain current licensure shall be considered a violation of
7 probation.

8 If Respondent owner's license expires or is cancelled by operation of law or otherwise at
9 any time during the period of probation, including any extensions thereof or otherwise, upon
10 renewal or reapplication Respondent owner's license shall be subject to all terms and conditions
11 of this probation not previously satisfied.

12 **8. License Surrender While on Probation/Suspension**

13 Following the effective date of this decision, should Respondent owner discontinue
14 business, Respondent owner may tender the premises license to the Board for surrender. The
15 Board or its designee shall have the discretion whether to grant the request for surrender or take
16 any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of
17 the license, Respondent will no longer be subject to the terms and conditions of probation.

18 Upon acceptance of the surrender, Respondent owner shall relinquish the premises wall and
19 renewal license to the Board within ten (10) days of notification by the Board that the surrender is
20 accepted. Respondent owner shall further submit a completed Discontinuance of Business form
21 according to Board guidelines and shall notify the Board of the records inventory transfer.

22 Respondent owner shall also, by the effective date of this decision, arrange for the
23 continuation of care for ongoing patients of the pharmacy by, at minimum, providing a written
24 notice to ongoing patients that specifies the anticipated closing date of the pharmacy and that
25 identifies one or more area pharmacies capable of taking up the patients' care, and by cooperating
26 as may be necessary in the transfer of records or prescriptions for ongoing patients. Within five
27 days of its provision to the pharmacy's ongoing patients, Respondent owner shall provide a copy
28 of the written notice to the Board. For the purposes of this provision, "ongoing patients" means

1 those patients for whom the pharmacy has on file a prescription with one or more refills
2 outstanding, or for whom the pharmacy has filled a prescription within the preceding sixty (60)
3 days.

4 Respondent owner may not apply for any new licensure from the Board for three (3) years
5 from the effective date of the surrender. Respondent owner shall meet all requirements applicable
6 to the license sought as of the date the application for that license is submitted to the Board.

7 Respondent owner further stipulates that he or she shall reimburse the Board for its costs of
8 investigation and prosecution prior to the acceptance of the surrender.

9 **9. Notice to Employees**

10 Respondent owner shall, upon or before the effective date of this decision, ensure that all
11 employees involved in permit operations are made aware of all the terms and conditions of
12 probation, either by posting a notice of the terms and conditions, circulating such notice, or both.
13 If the notice required by this provision is posted, it shall be posted in a prominent place and shall
14 remain posted throughout the probation period. Respondent owner shall ensure that any
15 employees hired or used after the effective date of this decision are made aware of the terms and
16 conditions of probation by posting a notice, circulating a notice, or both. Additionally,
17 Respondent owner shall submit written notification to the Board, within fifteen (15) days of the
18 effective date of this decision, that this term has been satisfied. Failure to submit such
19 notification to the Board shall be considered a violation of probation.

20 "Employees" as used in this provision includes all full-time, part-time,
21 volunteer, temporary and relief employees and independent contractors employed or
22 hired at any time during probation.

23 **10. Owners and Officers: Knowledge of the Law**

24 Respondent shall provide, within thirty (30) days after the effective date of this decision,
25 signed and dated statements from its owners, including any owner or holder of ten percent (10%)
26 or more of the interest in Respondent or Respondent's stock, and any officer, stating under
27 penalty of perjury that said individuals have read and are familiar with state and federal laws and
28 regulations governing the practice of pharmacy. The failure to timely provide said statements

1 under penalty of perjury shall be considered a violation of probation.

2 **11. Posted Notice of Probation**

3 Respondent owner shall prominently post a probation notice provided by the Board in a
4 place conspicuous and readable to the public. The probation notice shall remain posted during
5 the entire period of probation.

6 Respondent owner shall not, directly or indirectly, engage in any conduct or make any
7 statement which is intended to mislead or is likely to have the effect of misleading any patient,
8 customer, member of the public, or other person(s) as to the nature of and reason for the probation
9 of the licensed entity.

10 Failure to post such notice shall be considered a violation of probation.

11 **12. Violation of Probation**

12 If a Respondent owner has not complied with any term or condition of probation, the Board
13 shall have continuing jurisdiction over Respondent license, and probation shall be automatically
14 extended until all terms and conditions have been satisfied or the Board has taken other action as
15 deemed appropriate to treat the failure to comply as a violation of probation, to terminate
16 probation, and to impose the penalty that was stayed.

17 If Respondent owner violates probation in any respect, the Board, after giving Respondent
18 owner notice and an opportunity to be heard, may revoke probation and carry out the disciplinary
19 order that was stayed. Notice and opportunity to be heard are not required for those provisions
20 stating that a violation thereof may lead to automatic termination of the stay and/or revocation of
21 the license. If a petition to revoke probation or an accusation is filed against Respondent during
22 probation, the Board shall have continuing jurisdiction and the period of probation shall be
23 automatically extended until the petition to revoke probation or accusation is heard and decided.

24 **13. Completion of Probation**

25 Upon written notice by the Board or its designee indicating successful completion of
26 probation, Respondent license will be fully restored.


27 / /

28 / /

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Tony Park. I understand the stipulation and the effect it will have on my Pharmacy License, and Pharmacist License. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED: 5/28/15


PRITI CHATWANI for PUCHKAR
INTERNATIONAL LLC; PUCHKAR
INTERNATIONAL INC., dba "THE MEDICINE
SHOPPE" Respondent

I have read and fully discussed with Respondent Priti Chatwani the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: 05/28/2015


TONY PARK
Attorney for Respondent


1
2 ENDORSEMENT

3 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully
4 submitted for consideration by the Board of Pharmacy.

5
6 Dated:

Respectfully submitted,

7
8 KAMALA D. HARRIS
Attorney General of California
9 JOSHUA A. ROOM
Supervising Deputy Attorney General

10
11 
12 MARETTA WARD
Deputy Attorney General
Attorneys for Complainant

13 SF2013404287
14 41298376.doc
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Exhibit A

Accusation No. 4574

1 KAMALA D. HARRIS
Attorney General of California
2 JOSHUA A. ROOM
Supervising Deputy Attorney General
3 MARETTA WARD
Deputy Attorney General
4 State Bar No. 176470
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 703-1384
6 Facsimile: (415) 703-5480
Attorneys for Complainant

7
8 **BEFORE THE**
BOARD OF PHARMACY
9 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

10 In the Matter of the Citation Against:

Case No. 4574

11 **THE MEDICINE SHOPPE**
12 **3024 Pacific Avenue**
13 **Livermore, CA 94550**

A C C U S A T I O N

14 **Pharmacy License No. PHY 48618**

15 **PRITI CHATWANI**
16 **3024 Pacific Avenue**
17 **Livermore, CA 94550**

18 **Pharmacist License No. RPH 53463**

Respondent.

19
20 Complainant alleges:

21 **PARTIES**

22 1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity
23 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

24 2. On or about June 11, 2007, the Board of Pharmacy issued Pharmacy License Number
25 PHY 48618 to Puchkar International LLC; Pushkar International Inc., to do business as "The
26 Medicine Shoppe" (Respondent Medicine Shoppe).¹ The Pharmacy License was in full force and

27
28 ¹ The business entity was changed from an LLC to a corporation on September 26, 2009.

1 effect at all times relevant to the charges brought herein and will expire on June 1, 2015, unless
2 renewed.

3 3. On or about May 7, 2002, the Board of Pharmacy issued Pharmacist License Number
4 RPH 53463 to Priti Chatwani (Respondent Chatwani). The Pharmacist License was in full force
5 and effect at all times relevant to the charges brought herein and will expire on April 30, 2015,
6 unless renewed.

7 4. Records of the California State Board of Pharmacy show that Priti Chatwani, RPH
8 53463 is and has been President and Pharmacist-in-Charge of Respondent Medicine Shoppe since
9 June 11, 2007.

10 JURISDICTION

11 5. This Accusation is brought before the Board of Pharmacy (Board), Department of
12 Consumer Affairs, under the authority of the following laws. All section references are to the
13 Business and Professions Code unless otherwise indicated.

14 6. Section 4300(a) of the Code provides that every license issued by the Board may be
15 suspended or revoked.

16 7. Section 4300.1 of the Code states:

17 "The expiration, cancellation, forfeiture, or suspension of a board-issued license by
18 operation of law or by order or decision of the board or a court of law, the placement of a license
19 on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board
20 of jurisdiction to commence or proceed with any investigation of, or action or disciplinary
21 proceeding against, the licensee or to render a decision suspending or revoking the license."

22 8. Section 125.3 of the Code provides, in pertinent part, that the Board may request the
23 administrative law judge to direct a licentiate found to have committed a violation or violations of
24 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
25 enforcement of the case, with failure of the licentiate to comply subjecting the license to not being
26 renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be
27 included in a stipulated settlement.

28 / /

1 //

2 //

3 **STATUTORY AND REGULATORY PROVISIONS**

4 9. Section 4301 of the Code provides: "The board shall take again any holder of a
5 license who is guilty of unprofessional conduct or whose license has been procured by fraud or
6 misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited
7 to any of the following:

8 . . .

9 (c) Gross Negligence

10 . . .

11 (g) Knowingly making or signing any certificate or other document that falsely
12 represents the existence or nonexistence of a state of facts.

13 . . .

14 (j) The violation of any of the statutes of this state, of any other state, or of the
15 United States regulating controlled substances and dangerous drugs.

16 . . .

17 (o) Violating or attempting to violate, directly or indirectly, or assisting in or
18 abetting the violation of or conspiring to violate any provision or term of this chapter of the
19 applicable federal and state laws and regulations governing pharmacy, including regulations
20 established by the board or by any other state of federal regulatory agency."

21 10. Section 4076, subdivision (a) of the Code states:

22 "A pharmacist shall not dispense any prescriptions except in a container that meets the
23 requirements of the state and federal law and is correctly labeled with all of the following..."

24 . . .

25 "(7) The strength of the drug or the drug dispensed"

26 . . .

27 "(9) The expiration date of the effectiveness of the drug dispensed."

28

1 //

2 //

3 11. Section 4077, subdivision (a) of the Code states:

4 "Except as provided in subdivisions (b) and (c), no person shall dispense any dangerous
5 drug upon prescription except in a container correctly labeled with the information required by
6 section 4076."

7 12. Section 4113, subdivision (c) of the Code states:

8 "The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state
9 and federal laws and regulations pertaining to the practice of pharmacy."

10 13. California Code of Regulations, title 16, section 1711, provides:

11 "(a) Each pharmacy shall establish or participate in an established quality assurance
12 program which documents and assess medication errors to determine cause and an appropriate
13 response as part of a mission to improve the quality of pharmacy service and prevent errors."

14

15 "(e) The primary purpose of the quality assurance review shall be to advance error
16 prevention by analyzing, individually and collectively, investigative and other pertinent data
17 collected in response to a medication error to assess the cause and any contributing factors such
18 as system or process failures. A record of the quality assurance review shall be immediately
19 retrievable in the pharmacy. The record shall contain the following:

- 20 1. the date, location, and participants in the quality assurance review;
21 2. the pertinent data and other information relating to the medication error(s)
22 reviewed and documentation of any patient contact required by subdivision (c).
23 3. the findings and determinations generated by the quality assurance review; and,
24 4. recommend changes to pharmacy policy, procedure, systems, or processes, if
25 any.

26 "The pharmacy shall inform pharmacy personnel of changes to pharmacy policy,
27 procedure, systems, or processes made as a result of recommendations generated in the quality
28 assurance program."

1 //

2 //

3 14. California Code of Regulations, title 16, section 1715 provides:

4 The pharmacist-in-charge of each pharmacy shall complete a self-assessment of the pharmacy's
5 compliance with federal and state pharmacy law before July 1 of every off-numbered year.

6 15. California Code of Regulations, title 16, section 1716, provides:

7 Pharmacists shall not deviate from the requirements of a prescriptions except upon the prior
8 consent of the prescriber.

9 16. California Code of Regulations, title 16, section 1735.2, provides:

10 "(j) prior to allowing any drug product to be compounded in a pharmacy, the pharmacist-in-
11 charge shall complete a self-assessment for compounding pharmacies developed by the board."

12

13 "(f) The pharmacist performing or supervising compounding is responsible for the integrity,
14 potency, quality, and labeled strength of a compounded drug product until it is dispensed.

15 17. California Code of Regulations, title 16, section 1735.3, subdivisions (a)(3)(4)(6) and
16 (8) provide: that for each compounded drug product, the pharmacy records shall include the
17 identity of the pharmacy personnel who compounded the product, the identity of the pharmacist
18 reviewing the final drug product, the manufacturer, expiration date and lot number of each
19 component, and the expiration date of the final compounded drug product.

20 18. California Code of Regulations, title 16, section 1735.4, subdivision (a) provides: As
21 related to Business and Professions Code section 4076 subdivision (a)(9), the label of a
22 compounded drug product shall contain the expiration date of the effectiveness of the drug
23 dispensed.

24 19. California Code of Regulations, title 16, section 1735.7, subdivision (a) provides:
25 Any pharmacy engaged in compounding shall maintain written documentation sufficient to
26 demonstrate that pharmacy personnel have the skills and training required to properly and
27 accurately perform their assigned responsibilities relating to compounding.

28 //

1 //

2 //

3 20. California Code of Regulations, title 16, section 1735.8, provides:

4 "(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies
5 and procedures, a written quality assurance plan designed to monitor and ensure the integrity,
6 potency, quality, and labeled strength of compounded drug products.

7

8 "(c) The quality assurance plan shall include written standards for qualitative and
9 quantitative integrity, potency, quality, and labeled strength analysis of compounded drug
10 products. All qualitative and quantitative analysis reports for compounded drug products shall be
11 retained by the pharmacy and collated with the compounded record and master formula."

12 21. California Code of Regulations, title 16, section 1761, provides:

13 No pharmacist shall compound or dispense any prescription which contains any significant error,
14 omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription,
15 the pharmacist shall contact the prescriber to obtain the information needed to validate the
16 prescription.

17

18 **FACTUAL BACKGROUND**

19 22. On or about September 6, 2011, Patient "A" presented with a prescription for
20 liothyronine, thyroid medication, "T-3", at 3024 Pacific Avenue in Livermore, California, the
21 Respondent pharmacy establishment known as The Medicine Shoppe.^{2 3}

22 23. Respondent Chatwani compounded and filled the prescription, which was designated
23 as RX 6101993, on or about September 6, 2011. The prescription either read "150 mcg" (150
24 micrograms), or "150 mg" (150 milligrams). The compounded product was dispensed in a

25 ² Liothyronine or Liothyronine sodium is a synthetic version of one of the two hormones
26 made by the thyroid gland. It is used for treating persons who are hypothyroid (do not produce
enough thyroid hormones).

27 ³ Mcg refers to "micrograms." Mg refers to "milligrams." Micrograms are 1000 times
28 smaller than milligrams.

1 container that read "150 mcg," but Respondent Chatwani later reported that it was her intention to
2 compound ~~the~~ the product in a 150 mg strength.

3 24. Thereafter, Patient "A" began taking the medication as prepared by Respondents and
4 suffered injury as a result by having to be admitted to a hospital for 7 days.

5 25. Subsequent chemical lab analysis of the T-3 prescription prepared by Respondents
6 demonstrated the compounded capsules were neither 150 micrograms nor 150 milligrams.
7 The T-3 capsules contained on average 9406 mcg of liothyronine – a compound strength that was
8 dangerous to Patient "A" and resulted in her hospitalization.

9 26. On or about May 15, 2012, a Board Inspector conducted an inspection and
10 investigation of Respondent Medicine Shoppe. The inspector met with Respondent Chatwani and
11 noted that RX 6101993 was labeled as T-3 150 mcg but not compounded as such.

12 27. The Board Inspector requested the completed Community Pharmacy Self-
13 Assessment form and Compounding Pharmacy Self-Assessment form. The most recent
14 Community Pharmacy Self-Assessment available was completed on or about July 10, 2009.
15 There was no Compounding Pharmacy Self-Assessment completed. The version of the
16 Community Pharmacy Self-Assessment Respondent Chatwani used on or about July 10, 2009
17 contained sterile compounding questions only and did not apply to Respondent Medicine
18 Shoppe's non-sterile compounding.

19 28. Written training documentation for Respondent Pharmacist-in-Charge Chatwani was
20 not available during inspection.

21 29. The Board Inspector reviewed the pharmacy compounding log books. Respondent
22 Chatwani presented the page and the compound record book containing prescriptions
23 compounded for Patient "A". The Board Inspector noted the compounded records for RX
24 6101991, 6101992 and 6101993 were missing the following required items: (1) the identity of the
25 pharmacy personnel who compounded the drug product; (2) the identity of the pharmacist who
26 reviewed the final drug product; (3) the expiration date of the final compounded drug product;
27 and (4) the lot number for each compound component.

1 30. The Board Inspector asked Respondent Chatwani if she had completed any
2 compound product testing in the past year. She replied she had not. Respondent Chatwani
3 estimated her
4 pharmacy compounds ~~to be~~ ^{ge} approximately 50 medications each month. Respondent Chatwani
5 further indicated she was the only pharmacist checking compounding medications.

6 31. The Board Inspector asked Respondent Chatwani for the pharmacy's Compounding
7 Policy and Procedures. Respondent Chatwani could not locate the Compounding Policy and
8 Procedures.

9 32. The Board Inspector asked Respondent Chatwani about the incident involving Patient
10 "A" on September 6, 2011. Respondent Chatwani indicated the dose for liothyronine was 150
11 milligrams and stated that she compounded the prescription for 150 milligrams. However, the
12 label for Patient A on RX 6101993 showed "T-3 150 mcg."

13 33. The Board Inspector reviewed the Quality Assurance Report for RX 6101993 for the
14 incident related to Patient "A". The document was missing the date of the review, recorded the
15 complaint as "Mislabel (T-3 150 mcg)" and contained only the comment "Patient states-wrong
16 strength." No other details were provided. There were no findings, determinations, or
17 recommended changes to policies, procedures, systems, or processes.

18
19 **FIRST CAUSE FOR DISCIPLINE**

20 **(Unprofessional Conduct – No Self-Assessment By Pharmacist-In-Charge)**

21 34. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or
22 4113(c), and/or California Code of Regulations, title 16, section 1715 in that Respondents failed
23 to complete a self-assessment as pharmacist-in charge to ensure pharmacy compliance with state
24 and federal law.

25
26 **SECOND CAUSE FOR DISCIPLINE**

27 **(Unprofessional Conduct – No Compounding Self-Assessment)**

35. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or 4113(c), and/or California Code of Regulations, title 16, section 1735.2(j) in that Respondents failed to complete a self-assessment for compounding pharmacies prior to allowing any drug to be compounded in the pharmacy.

THIRD CAUSE FOR DISCIPLINE

(Unprofessional Conduct – Variation from Prescription)

36. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or 4113(c), and/or California Code of Regulations, title 16, section 1716, in that Respondents deviated from the requirements of a prescription without the consent of the prescriber.

FOURTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct – Uncertain Prescription)

37. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or 4113(c), and/or California Code of Regulations, title 16, section 1761, in that Respondents compounded or dispensed a prescription which contained a significant error, omission, irregularity, uncertainty, ambiguity or alteration. Specifically, Respondents compounded and dispensed RX 6101993 to Patient "A" without accurately confirming the dose with the prescriber when the prescription appeared to be written with an uncertain dose.

FIFTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct – Quality Assurance Review Lack of Detail)

38. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or 4113(c), and/or California Code of Regulations, title 16, section 1711(e), in that Respondents' Quality Assurance review record for RX 6101993 dispensed to Patient "A" on September 6, 2011, lacked a date, participants, pertinent data reviewed relating to the reported medication error, findings, determinations, and recommendations on changes to or maintaining pharmacy policies, procedures, systems or processes.

/ /

1 //
2 //
3 //
4 //

SIXTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Dispensing Dangerous Drug Incorrectly)

39. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or 4113(c), and/or 4076(a)(7)/4077 in that Respondents labeled and dispensed RX 6101993 to Patient "A" as T-3 150 mcg when in fact the product was not compounded as such and therefore did not meet state and federal labeling requirements.

SEVENTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Drugs Lacking Quality or Strength)

40. Respondents are subject to disciplinary action under section 4301 and/or 4113(c) in that Respondents labeled RX 6101993 for Patient "A" as T-3 150 mcg when the compounded medication contained an average of T-3 9,406 mcg per capsule.

EIGHTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Failure to Exercise Professional Judgment)

41. Respondents are subject to disciplinary action under section 4301 and/or 4306.5, and/or 4113(c), in that according to the compound record and a statement from Respondents, Respondents failed to appropriately exercise professional judgment in preparing a compounded medication that matched neither the prescription authorized by the prescriber nor the label placed on the container.

NINTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Gross Negligence)

42. Respondents are subject to disciplinary action under sections 4301(c), and/or 4113(c), in that according to the compound record and a statement from Respondents,

1 Respondents failed to appropriately exercise professional judgment in preparing a compounded
2 medication that matched neither the prescription authorized by the prescriber nor the label placed
3 on the container.

4 / /

5 **TENTH CAUSE FOR DISCIPLINE**

6 **(Unprofessional Conduct – No Expiration Dates on Compounded Drugs Labels)**

7 43. Respondents are subject to disciplinary action under section 4301(j) and/or (o),
8 4076(a)(9)/4077, and/or 4113(c), and/or California Code of Regulations, title 16, section
9 1735.4(a) in that Respondents labeled and dispensed RX 6101991, RX 6101992, and RX
10 6101993 to Patient "A" with no product expiration date on the label as required.

11
12 **ELEVENTH CAUSE FOR DISCIPLINE**

13 **(Unprofessional Conduct – Compound Record Missing Required Items)**

14 44. Respondents are subject to disciplinary action under section 4301(j) and/or (o),
15 and/or 4113(c) and/or California Code of Regulations, title 16, section 1735.3(a)(3)(4)(6)(8) and
16 (9), in that Respondents labeled and dispensed RX 6101991, RX 6101992, and RX 6101993 to
17 Patient "A" when the compound record for each was missing: the identity of the pharmacy
18 personnel who compounded the product; the identity of the pharmacist reviewing the final drug
19 product; the lot number of each component.

20
21 **TWELFTH CAUSE FOR DISCIPLINE**

22 **(Unprofessional Conduct – No Documentation of Training for Compounding Staff)**

23 45. Respondents are subject to disciplinary action under section 4301(j) and/or (o),
24 and/or 4113(c), and/or California Code of Regulations, title 16, section 1735.7(a), in that on May
25 15, 2012, Respondent Chatwani stated during an inspection, and the Board Inspector determined,
26 that there was no compounding training documentation on record for Respondent Chatwani as the
27 compounding pharmacist.

28 / /

1 //
2 //
3 //
4 //

THIRTEENTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - No Compounding Quality Assurance)

46. Respondents are subject to disciplinary action under section 4301(j) and/or (o), and/or 4113(c), and California Code of Regulations, title 16, section 1735.8(c), in that Respondents, during an inspection by the Board on May 15, 2012, had no qualitative or quantitative Compounding Quality Assurance records available from the past year, for a reported volume of approximately 50 compounded prescriptions each month.

FOURTEENTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Responsibility for Integrity, Potency and Quality of Drug)

47. Respondents are subject to disciplinary action under section 4301 and/or California Code of Regulations, title 16, section 1735.2(f), in that on or about September 6, 2011, Respondents dispensed a compounded product pursuant to RX 6101993 for Patient "A" that was lacking in integrity, potency, quality, and/or label strength.

FIFTEENTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Making a False Statement)

48. Respondents are subject to disciplinary action under section 4301(g) and/or 4113(c) in that there were conflicts in various records made and provided by Respondents.

• On or about June 13, 2012, Respondents provided a statement about the compounding of RX 6101993 containing information which conflicted with the compounded record provided by the Respondents on May 15, 2012.

- The compound record for RX 6101993 stated 4.5 grams of liothyronine powder was used to compound RX 6101993. The Compound Rx Report provided by Respondents and the patient receipt stated .0450 grams of liothyronine powder was used to compound RX 6101993.

• The compound record for RX 6101992 stated 0.0008 grams of liothyronine powder and 7.17 grams of cellulose were used to compound RX 6101992. The Compound Rx Report provided by Respondents and the patient receipt for RX 6101992 stated 0.008 grams of liothyronine powder and 5.067 grams of acidophilus lactobacillus powder 1BU/gram was used to compound RX 6101992.

OTHER MATTERS

49. To determine the level of discipline, if any, to be imposed on Respondent Medicine Shoppe and/or Respondent Chatwani (collectively Respondents), Complainant further alleges:

a. On or about December 15, 2010, Citation No. CI 2010 46106, was issued to Respondent Medicine Shoppe, for (1) dispensing dangerous drugs incorrectly labeled, Bus. & Prof. Code Section 4077(a)/4076(a)(11)(A); (2) Varying from prescription, California Code of Regulation, Title 16, Section 1716; (3) Failure to have written policies and procedures, Bus. & Prof. Code Section 4101(b); (4) Failing to comply with self-assessment form, California Code of Regulations, Title 16 Section 1715(a); (4) unprofessional conduct – false representation, Bus. & Prof. Code Section 4301(g). A fine of \$5,000 was issued and paid.

b. On or about December 15, 2010, Citation No. CI 2012 53638 was issued to Respondent Chatwani, for (1) dispensing dangerous drugs incorrectly labeled, Bus. & Prof. Code Section 4077(a)/4076(a)(11)(A); (2) Varying from prescription, California Code of Regulation, Title 16, Section 1716; (3) Failure to have written policies and procedures, Bus. & Prof. Code Section 4101(b); (4) Failing to comply with self-assessment form, California Code of Regulations, Title 16 Section 1715(a); (4) unprofessional conduct – false representation, Bus. & Prof. Code Section 4301(g). A fine of \$5,000 was issued and paid.

/ /

/ /

11


1 //
2 //
3 //
4 //
5 //
6 //

7 **PRAYER**

8 **WHEREFORE**, Complainant requests that a hearing be held on the matters herein alleged,
9 and that following the hearing, the Board of Pharmacy issue a decision:

- 10 1. Revoking or suspending Pharmacy License Number PHY 48618, issued to
11 Respondent Medicine Shoppe;
12 2. Revoking or suspending Pharmacist License Number RPH 53463, issued to
13 Respondent Chatwani;
14 3. Ordering Respondents to pay the Board of Pharmacy the reasonable costs of the
15 investigation and enforcement of this case, pursuant to Business and Professions Code section
16 125.3;
17 4. Taking such other and further action as is deemed necessary and proper.

18
19
20
21 DATED: 9/22/14


VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

22
23
24
25 SF2013404287
26 41080679.docx
27
28